Urologische Klinik München Planegg
Welcome,         Profile    Billing    Logout  
 0 Trials 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ivanyi, Philipp
PREPARE, NCT03013946 / 2016-000399-28: Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line Therapy

Terminated
3
121
Europe
Concomitant coaching
AIO-Studien-gGmbH, Pfizer, Crolll Gmbh
Renal Cell Carcinoma, Metastatic, Renal Cell Cancer, Recurrent
01/24
01/24
JADE, NCT06256588: A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

Recruiting
3
864
Europe, Canada, Japan, US, RoW
Dostarlimab, Placebo
GlaxoSmithKline
Neoplasms, Head and Neck
05/28
07/29
ARASAFE, NCT05676203: A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC Patients

Active, not recruiting
3
250
Europe
Standard ADT (androgen deprivation therapy), Standard Darolutamide, Docetaxel
Jena University Hospital, Bayer
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
07/25
01/27
TRABTRAP, NCT05597917 / 2020-005858-21: tTF-NGR Randomized Study - STS

Recruiting
3
126
Europe
Trabectedin, Yondelis, tTF-NGR
Universität Münster, Anturec Pharmaceuticals GmbH
Soft Tissue Sarcoma
08/26
12/26
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ivanyi, Philipp
PREPARE, NCT03013946 / 2016-000399-28: Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line Therapy

Terminated
3
121
Europe
Concomitant coaching
AIO-Studien-gGmbH, Pfizer, Crolll Gmbh
Renal Cell Carcinoma, Metastatic, Renal Cell Cancer, Recurrent
01/24
01/24
JADE, NCT06256588: A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

Recruiting
3
864
Europe, Canada, Japan, US, RoW
Dostarlimab, Placebo
GlaxoSmithKline
Neoplasms, Head and Neck
05/28
07/29
ARASAFE, NCT05676203: A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC Patients

Active, not recruiting
3
250
Europe
Standard ADT (androgen deprivation therapy), Standard Darolutamide, Docetaxel
Jena University Hospital, Bayer
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
07/25
01/27
TRABTRAP, NCT05597917 / 2020-005858-21: tTF-NGR Randomized Study - STS

Recruiting
3
126
Europe
Trabectedin, Yondelis, tTF-NGR
Universität Münster, Anturec Pharmaceuticals GmbH
Soft Tissue Sarcoma
08/26
12/26

Download Options